Among patients with grade group 1 prostate cancer, those belonging to higher risk groups were more likely to have adverse pathology and die from their disease. About 1 in 6 patients with grade group 1 ...

WEDNESDAY, Aug. 6, 2025 (HealthDay News) -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online July ...

SAN FRANCISCO -- Prophylactic whole-pelvic radiation therapy (RT) did not perform as expected for patients with unfavorable intermediate-risk or favorable high-risk prostate cancer, according to ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...

Stage 2 prostate adenocarcinoma is localized, with a nearly 100% five-year relative survival rate. Diagnosis uses the TNM system, PSA levels, and Gleason score to determine cancer stage and risk.

People with localized prostate cancer treated according to guidelines developed by an international panel of doctors are more likely to die of something other than the disease, new research shows. A ...